Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial

Adding ublituximab to ibrutinib resulted in a higher overall response rate (median follow-up of 41.6 months) of 83% (53/64) (83%) in the ublituximab + ibrutinib group vs. 65% (40/62) in the ibrutinib group (p=0·020).

Source:

The Lancet Haematology